Literature DB >> 8178903

Hormonal implants: contraception for a new century.

P D Darney1.   

Abstract

Subdermal implants are contraceptive systems that release low, stable amounts of synthetic progestins from Silastic or other materials for periods of months to several years. Unlike other hormonal delivery systems, they do not cause unnecessary peaks in progestin levels and do not use estrogens, and thus their health risks are minimal. Norplant has been studied more extensively than any other subdermal contraceptive implant. More than 60,000 women have participated in clinical trials, which demonstrated that this approach is one of the most effective reversible contraceptive methods available (1% pregnancy rate in 5-year users). The implant also reduces the incidence of ectopic pregnancy to a level much below noncontraceptive users and about equivalent to TCu380A intrauterine device users. Exposure to the sustained, low dose of levonorgestrel delivered by Norplant has shown only minor metabolic changes. Side effects are minor but often bothersome, causing some discontinuation of the method. First-year continuation rates range from 76% to 90%. Fertility return after discontinuation is prompt. Difficulty in removal of the implant capsules by the less experienced practitioner has motivated researchers to develop systems that are easier to use, less obvious under the skin, and biodegradable. The Norplant 2 system is faster, easier, and less painful to insert and remove. Implants under investigation release desogestrel and other progestins; Capronor and subdermal norethindrone pellets are biodegradable systems.

Entities:  

Keywords:  Clinical Research; Clinical Trials; Contraception; Contraception Research; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Family Planning; Levonorgestrel

Mesh:

Substances:

Year:  1994        PMID: 8178903     DOI: 10.1016/s0002-9378(94)05016-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Controlled-release systemic delivery - a new concept in cancer chemoprevention.

Authors:  Ramesh C Gupta; Shyam S Bansal; Farrukh Aqil; Jeyaprakash Jeyabalan; Pengxiao Cao; Hina Kausar; Gilandra K Russell; Radha Munagala; Srivani Ravoori; Manicka V Vadhanam
Journal:  Carcinogenesis       Date:  2012-06-13       Impact factor: 4.944

2.  Ultrasound-guided removal of Implanon devices.

Authors:  T Persaud; M Walling; T Geoghegan; O Buckley; H Stunell; W C Torreggiani
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

Review 3.  Biocompatibility issues of implantable drug delivery systems.

Authors:  H Park; K Park
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

Review 4.  Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Manicka V Vadhanam
Journal:  Cancer Lett       Date:  2013-02-19       Impact factor: 8.679

Review 5.  Contraceptive Implant Migration and Removal by Interventional Radiology.

Authors:  Salina Zhang; Pelin Batur; Charles Martin; Paul J Rochon
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 6.  Safety and Benefits of Contraceptives Implants: A Systematic Review.

Authors:  Morena Luigia Rocca; Anna Rita Palumbo; Federica Visconti; Costantino Di Carlo
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.